Lyophilised vs Compressed ODTs: Which Manufacturing Route Fits Your Molecule?

A molecule may be well suited to an orally disintegrating tablet (ODT), yet prove difficult to develop using the first manufacturing process considered. A high drug load could compromise tablet structure. A moisture-sensitive API may struggle during aqueous processing. A formulation designed for rapid disintegration could become too fragile for routine handling.

These problems often emerge during feasibility studies, when the choice between lyophilisation and compression starts to influence the entire development programme.

Both routes can produce effective ODTs, but they differ in how the tablet is formed, the drug properties they can accommodate and the processing challenges they introduce. For pharmaceutical companies, understanding these differences early can prevent costly formulation changes further down the line.

How do lyophilised and compressed ODTs differ?

The distinction begins with how the tablet acquires its structure.

Lyophilised ODTs are generally produced by preparing a solution or suspension of the active pharmaceutical ingredient (API) and selected excipients. The formulation is dispensed into moulds or blister cavities, frozen and subjected to freeze-drying. Water is removed through sublimation, leaving a highly porous matrix that allows saliva to penetrate quickly.

This structure is responsible for one of the main benefits of lyophilized ODT technology: exceptionally rapid disintegration, often within seconds.

Compressed ODTs are produced by compressing powder blends or granules. These formulations typically rely on superdisintegrants, such as crospovidone or croscarmellose sodium, to encourage the tablet to break apart when exposed to saliva.

Compression produces a relatively dense tablet, generally offering better mechanical strength. The challenge is achieving that strength while retaining rapid disintegration.

A 2026 review describes the trade-offs between ODT technologies in terms of drug loading, mechanical strength, manufacturing costs and process robustness. These characteristics vary by formulation, making early experimental assessment essential. [1]

Lyophilised vs compressed ODTs: How do they compare? [1,2]

This simply provides a starting point. Actual product performance depends on the API, excipient system, tablet dimensions and manufacturing conditions.

Disintegration speed: How fast is fast enough?

Lyophilised tablets can disintegrate within seconds because their porous structure allows saliva to enter the matrix with little resistance.

InstaPill's proprietary lyophilised ODT platform, for example, reports dispersion within 3–10 seconds. This is a platform-specific performance claim and should be assessed for each developed formulation. [3]

Compressed ODTs can also achieve rapid disintegration. Their performance depends on selecting suitable superdisintegrants and controlling compression force.

In a comparative study involving deferasirox, researchers found that lyophilised tablets disintegrated within five seconds and showed faster dissolution than directly compressed formulations. The findings illustrate how manufacturing route can affect the performance of the same API. [4]

The US FDA recommends an in-vitro disintegration time of approximately 30 seconds or less for products labelled as ODTs. [5]

That benchmark creates an important distinction for developers. A compressed formulation that reliably meets the intended product profile may be entirely appropriate. Lyophilisation becomes particularly attractive when very rapid dispersion and the resulting tablet characteristics offer a meaningful product advantage.

Disintegration time also needs to be considered separately from dissolution and absorption. A tablet that breaks apart quickly won't necessarily produce a faster clinical response.

Tablet strength: The cost of a porous structure

The same porosity that helps lyophilised ODTs disperse quickly can make them mechanically fragile but are not friable, able to be handled by the patient and protected by the pack during storage and transport. 

A study published in the International Journal of Pharmaceutics found an inverse relationship between disintegration and mechanical strength among the lyophilised tablets examined. Improving one attribute can place pressure on the other. [6]

Freeze-dried formulations therefore need sufficient matrix strength to withstand handling and removal from packaging. Their sensitivity to environmental moisture must also be considered.

Compressed ODTs generally have greater mechanical strength, although excessive compression can delay disintegration.

A 2025 formulation study of compressed aripiprazole ODTs reported tablet hardness of 48.35 N, friability of 0.77% and disintegration within 66 seconds. The results show why mechanical strength and disintegration need to be assessed together during formulation optimisation. [7]

For either technology, the formulation has to perform consistently after manufacturing, storage and distribution. A promising laboratory disintegration time is only one part of that assessment.

Which molecules suit lyophilised ODTs?

Lyophilisation may be particularly useful when the target product profile calls for very rapid dispersion or when the API presents specific processing requirements.

Low-dose, potent APIs can be attractive candidates because smaller drug quantities may be easier to incorporate without compromising the freeze-dried matrix. However, the distribution of the API within the liquid formulation must remain uniform during dispensing and freezing.

Selected heat-sensitive molecules may benefit from the relatively low-temperature drying process. This advantage requires qualification. Freezing, concentration changes and exposure to liquid processing conditions can also affect stability.

Molecules requiring specialised taste-masking approaches may be candidates where the formulation can accommodate an appropriate taste-masking system while preserving disintegration and structural integrity.

Recent research has also explored lyophilised systems incorporating self-nanoemulsifying formulations for poorly soluble drugs. These approaches remain highly formulation-dependent, and their proposed benefits require product-specific evidence. [1]

The critical question is whether the API remains stable and the matrix retains its required properties throughout processing. For example, a molecule with poor aqueous stability may require substantial formulation work before it becomes suitable for a process involving an aqueous solution or suspension.

Freeze-drying cannot compensate for an API that degrades during preparation.

When does compression make more sense?

Compression offers practical advantages for APIs that can tolerate the tableting process and achieve the required disintegration profile through conventional excipient systems.

It may be preferable for higher-dose formulations where the amount of drug would challenge a freeze-dried matrix. A molecule with suitable powder properties may also be easier to develop using established compression processes.

Mechanical strength can be another deciding factor. Where handling requirements are demanding, compressed ODTs may offer greater flexibility, provided the formulation retains acceptable disintegration performance.

Manufacturing economics matter too. Compression uses widely established pharmaceutical equipment and may provide a lower-cost route for suitable products. Lyophilisation requires specialised freeze-drying equipment, process development and carefully controlled drying cycles. [1, 2]

However, cost comparisons should be made at the product level. Yield, packaging requirements, manufacturing scale and the intended commercial value of the formulation all affect the final economics.

What should determine the manufacturing route?

A useful feasibility study should answer several questions before a company commits to either technology.

• Start with API behaviour. Solubility, stability, particle characteristics and sensitivity to processing conditions influence what is technically possible. An API that performs well in a compressed blend may behave differently in a liquid formulation subjected to freezing.
• Examine dose and formulation space. Drug loading can affect matrix strength, tablet dimensions and disintegration. Higher concentrations may leave insufficient room for the excipients needed to produce a reliable lyophilised structure.
• Define the intended patient experience. How quickly must the tablet disperse? Is taste masking essential? What mouthfeel is acceptable? These requirements should come from the target product profile rather than assumptions about either technology.
• Test commercial feasibility early. Packaging, moisture sensitivity, process reproducibility and manufacturing costs can change the attractiveness of a formulation that initially performs well in the laboratory.
• 

Rosaleen McLaughlin, Chief of InstaPill's Scientific Advisory Board, has previously highlighted the importance of keeping commercial translation in view during formulation development:

“Quite often people develop very complex solutions that aren’t then translatable… You’ve got to keep the end goal in mind and not let it become an academic exercise.”

Her observation captures a recurring risk in pharmaceutical development. A technically sophisticated formulation has limited commercial value if it cannot be produced reliably at the required scale.

For ODT programmes, that assessment needs to begin during feasibility, when changes to the formulation and process are still relatively manageable.

Evaluating a lyophilised ODT manufacturing partner

Pharmaceutical companies searching for the best lyophilized ODT manufacturer should examine the partner's experience with the intended molecule, the proposed development process and commercial manufacturing requirements.

InstaPill specialises in lyophilised orally disintegrating tablets through its proprietary InstaPill® platform. Its formulation development experience spans reported dose strengths from 0.06 mg to 200 mg, including work on taste masking and a small peptide molecule. [3]

The company's capabilities cover formulation feasibility, development, regulatory support and commercial manufacturing at its Bengaluru facility.

For sponsors considering lyophilisation, this experience offers a basis for evaluating whether a molecule can be accommodated within the technology and what development work may be needed.

The earlier that assessment takes place, the more opportunity there is to address potential stability, drug-loading or processing problems before they become expensive development obstacles.

The manufacturing decision starts with the molecule

The benefits of lyophilised ODTs are strongest when rapid dispersion, formulation requirements and the intended patient experience favour a freeze-dried matrix. Compression remains a practical option for many APIs, particularly where mechanical strength, drug loading and manufacturing economics are important.

Some molecules could work with either process. The deciding factors may emerge only after comparative feasibility work.

For pharmaceutical developers, the priority is to establish which technology can meet the intended product profile reproducibly, with an acceptable development and commercial manufacturing pathway.

That decision is worth making before formulation development moves too far in one direction.